Background Lupus nephritis (LN) is a common manifestation of systemic lupus erythematosus (SLE), with 10–30% progressing to end-stage renal disease (ESRD) and requiring dialysis. Kidney ...

Background This study aimed to investigate the clinical characteristics, outcomes, and risk factors of patients with a rare but fatal manifestation of systemic lupus erythematosus (SLE), diffusive ...

Background Belimumab in conjunction with mycophenolate mofetil has been proven to be effective for treating systemic lupus erythematosus (SLE) in several randomized controlled trials. Usefulness of ...

Background Although the safety profile of COVID-19 vaccines was shown to be acceptable in the clinical trials, risk and benefit of the vaccines in patients with systemic lupus erythematosus (SLE) are ...

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with varied clinical manifestations and complex pathogenesis. SLE has a significant impact on morbidity, mortality and ...

Background Previous US study presented a claims-based algorithm, consisted with comorbidities and medication information, to classify systemic lupus erythematosus (SLE) severity as mild, moderate or ...

Background Recently, vitamin D has been shown to play an important role in the immune responses, increasing evidence that it can contribute to the pathogenesis of systemic lupus erythematosus (SLE) as ...

Background To compare the prognosis of SLE patients who achieve clinically quiescent following treatment, with or without serologically active. Methods We categorized SLE patients from Lupus Clinic of ...

Background Systemic lupus erythematosus is a chronic-systemic autoimmune disease that may affect different organ and organ system. Pathogenesis of SLE is not well understood but high inflammatory ...

Background Interstitial pneumonia with autoimmune features (IPAF) is a research classification proposed by the European Respiratory Society and American Thoracic Society Task Force for those patients ...

Objective To describe the pharmacodynamic monitoring of (immuno)proteasome inhibition following treatment with bortezomib in a therapy-refractory systemic lupus erythematosus (SLE) patient with ...